Publications by authors named "R Eagle"

Purpose: To report the detailed histopathology of 2 enucleated eyes from 2 patients who developed severe visual loss associated with retinal hemorrhages, vessel sheathing, and vascular nonperfusion after administration of an initial dose of intravitreal pegcetacoplan, and propose, with supportive histopathology, the pathogenesis of the clinical syndrome previously termed hemorrhagic occlusive retinal vasculitis.

Design: Case series.

Subjects: Two enucleated eyes from 2 patients treated with intravitreal pegcetacoplan.

View Article and Find Full Text PDF

Purpose: To compare the clinical outcomes of children with unilateral retinoblastoma (Rb) and high-risk histopathology features (HRHF) following upfront enucleation with/without adjuvant chemotherapy, and investigate cases locally considered non-HRHF but converted to a standardized HRHF definition.

Design: Retrospective multinational clinical cohort study.

Methods: Children with Rb who presented to 21 centers from 12 countries between 2011-2020, and underwent primary enucleation were recruited.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze high-risk histopathological features in eyes with retinoblastoma (RB) after enucleation and compare patient outcomes globally.
  • A total of 1,426 RB cases were reviewed, revealing significant differences in histopathological features across continents, with Asia showing the highest rates of massive choroidal invasion and optic nerve invasion.
  • The findings indicated that patients from South America and Asia faced greater risks of tumor recurrence, systemic metastasis, and mortality compared to those from Australia, Europe, and North America.
View Article and Find Full Text PDF

Purpose: Retinoblastoma is the most common intraocular malignancy in children. Although new chemotherapeutic approaches have improved ocular salvage rates, novel therapies are required for patients with refractory intraocular and metastatic disease. Chimeric antigen receptor (CAR) T cells targeting glypican-2 (GPC2) are a potential new therapeutic strategy.

View Article and Find Full Text PDF